Grant: Project Grant

Using modern molecular technologies - advanced tools that help us look very closely at what's happening inside your body - endometrial cancers (EC) can be categorized into 4 distinct subgroups based on their molecular features. Molecular features refer to the tiny building blocks that make up the endometrial cancers. We are participating in a program of clinical trials (the RAINBO Program) designed to match treatments to the molecular type of EC. In the proposed clinical trial called RAINBO-ORANGE, we will evaluate a novel treatment strategy in individuals with EC that are classified as no specific molecular subtype (NSMP). These tumours lack other defining molecular markers and only express hormone receptors on the surface of the cancer cells. Hormone receptors respond to specific hormones. Standard treatment for stage 2 or 3 EC typically includes surgery followed by radiation and chemotherapy. However, data indicate that hormone-based therapy may be a useful treatment option in NSMP EC that are hormone receptor-positive. RAINBO-ORANGE will investigate if surgery followed by radiotherapy and a type of oral endocrine therapy called progestins will lead to similar cancer control as surgery followed by radiotherapy and chemotherapy in patients with NSMP, estrogen receptor-positive EC. Further, the trial will examine whether radiotherapy and oral progestin tablet therapy are associated with fewer side effects and better quality of life than radiotherapy and chemotherapy. Tumour tissue will be collected on all trial participants, and analysis will help us better understand which tumours are more likely to recur and which treatment to use. The trial is led by University College London in the UK and will be led in Canada by the Canadian Cancer Trials Group. A total of 100 patients from 14 Canadian centres will be enrolled.